Genetic and Clinical Data Linking Severe COVID-19 to Polymyositis

Supplementary data from a multilevel study investigating a potential causal link between severe COVID-19 and polymyositis. The dataset includes results from Mendelian randomization analyses, multi-omic mediator screening, and hematological profiles from 108 hospitalized COVID-19 patients. The data was authored by Miaomiao Chen and last updated on April 9, 2026.

Use Cases

• Validate genetic causal inference based on Mendelian randomization odds ratios
• Investigate candidate molecular mediators like KIAA1024 and RNASE1 mentioned in the description
• Compare hematological indices such as neutrophil and lymphocyte counts between severe and non-severe COVID-19 cases
• Explore functional enrichment pathways like ErbB signaling implicated in the analysis

Strengths

• Includes genetic data from GWAS studies for severe COVID-19, polymyositis, and 91 inflammatory proteins
• Clinical data covers 108 hospitalized patients with PCR-confirmed COVID-19
• Results include specific odds ratios (IVW OR=1.65) and adjusted p-values for hematological associations

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The authors note findings are preliminary clues requiring validation with larger cohorts

Provenance

Source

figshare

Collection Method

Genetic instruments from GWAS; clinical data from a single-center retrospective cohort analysis.

Freshness

Last updated 2026-04-09 05:20:02